 | |
| Clinical data | |
|---|---|
| Other names | ZK-115194; Cycloestradiol; 14α,17α-Ethano-17β-estradiol; 14α,17α-Ethanoestra-1,3,5(10)-triene-3,17β-diol; 14,21-Cyclo-19-norpregna-1,3,5(10)-triene-3,17α-diol |
| Routes of administration | By mouth[1] |
| Drug class | Estrogen |
| Pharmacokinetic data | |
| Bioavailability | 33 ± 19%[1] |
| Eliminationhalf-life | 28.7 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H26O2 |
| Molar mass | 298.426 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cyclodiol (developmental code nameZK-115194; also known as14α,17α-ethano-17β-estradiol) is asyntheticestrogen which was studied in the 1990s and was never marketed.[2][1][3] It is aderivative ofestradiol with abridge between the C14α and C17α positions.[2][1][3][4] Cyclodiol has 100% of therelative binding affinity of estradiol for the humanERα and similartransactivational capacity as estradiol at the receptor.[2] It has comparablepotency to estradiol when administered bysubcutaneous injection.[2] The drug showsgenotoxicity similarly to estradiol.[2][4] Cyclodiol showed anabsolute bioavailability of 33 ± 19% and anelimination half-life of 28.7 hours inpharmacokinetic studies in women.[1]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
